LGC offers an integrated in vitro anti-infective development service. Supporting molecules from discovery, through to before and after launch.
Compound structure elucidation
MIC panel screening against clinically relevant strains to identify spectrum of activity/ aid molecule development
Antimicrobial efficacy testing (Time-Kill, serial passage, mutation frequency testing)
Mode of Action analysis (enzymatic and knock out mutant testing)
Compound toxicity testing (against hepatic cell lines/yeast)
Protein binding assessments / drug-drug interactions / ADA analysis
Clinical trial support (including bacterial counts, identification, isolate extraction/storage and MIC analysis)
Antimicrobial susceptibility surveillance (regulatory requirement for all antimicrobial NDA submissions (FDA, EMA and others))
Post marketing surveillance
To discuss your project with our team of specialists or to find out more, please contact us
LGC operates out of 22 countries, with laboratories and centres across Europe and the US, as well as sites in Brazil, China and India.